Stereotaxis/$STXS
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Stereotaxis
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Ticker
$STXS
Sector
Primary listing
AMEX
Industry
Health Care Equipment & Supplies
Headquarters
Employees
139
ISIN
US85916J4094
Website
Stereotaxis Metrics
BasicAdvanced
$189M
-
-$0.31
1.46
-
Price and volume
Market cap
$189M
Beta
1.46
52-week high
$2.72
52-week low
$1.54
Average daily volume
256K
Financial strength
Current ratio
1.07
Quick ratio
0.616
Long term debt to equity
64.579
Total debt to equity
71.771
Profitability
EBITDA (TTM)
-22.602
Gross margin (TTM)
53.41%
Net profit margin (TTM)
-92.19%
Operating margin (TTM)
-86.05%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-34.75%
Return on equity (TTM)
-179.82%
Valuation
Price to revenue (TTM)
6.898
Price to book
65.68
Price to tangible book (TTM)
-23.56
Price to free cash flow (TTM)
-23.828
Free cash flow yield (TTM)
-4.20%
Free cash flow per share (TTM)
-9.23%
Growth
Revenue change (TTM)
1.50%
Earnings per share change (TTM)
18.97%
3-year revenue growth (CAGR)
-6.29%
10-year revenue growth (CAGR)
-2.70%
3-year earnings per share growth (CAGR)
15.68%
10-year earnings per share growth (CAGR)
4.04%
What the Analysts think about Stereotaxis
Analyst ratings (Buy, Hold, Sell) for Stereotaxis stock.
Stereotaxis Financial Performance
Revenues and expenses
Stereotaxis Earnings Performance
Company profitability
Stereotaxis News
AllArticlesVideos
First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology
GlobeNewsWire·3 days ago
Stereotaxis Reports 2025 First Quarter Financial Results
GlobeNewsWire·2 months ago
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stereotaxis stock?
Stereotaxis (STXS) has a market cap of $189M as of July 04, 2025.
What is the P/E ratio for Stereotaxis stock?
The price to earnings (P/E) ratio for Stereotaxis (STXS) stock is 0 as of July 04, 2025.
Does Stereotaxis stock pay dividends?
No, Stereotaxis (STXS) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Stereotaxis dividend payment date?
Stereotaxis (STXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Stereotaxis?
Stereotaxis (STXS) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.